Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Bolus, mealtime dosages of a new formulation of insulin paired with recombinant human hyaluronidase to speed insulin?s absorption and action led to significantly reduced postprandial, glycemic excursions in a randomized study of 113 patients with type 1 diabetes.
The hyaluronidase plus insulin formulation also resulted in a "flatter" daytime glucose profile, and led to a statistically significant reduction in hypoglycemic events, Dr. Jay S. Skyler said at the annual meeting of the European Association for the Study of Diabetes. In addition to these improvements in insulin management, the study results also showed that the hyaluronidase formulation was noninferior to insulin alone for reducing hemoglobin A1c levels, and also had a similar safety and tolerability profile in type 1 patients, said Dr. Skyler, professor and deputy director of the diabetes research institute of the University of Miami.
http://www.clinicalendocrinologynew...ursions/74d5016961f4c5f32d80b1056e5622a3.html
The hyaluronidase plus insulin formulation also resulted in a "flatter" daytime glucose profile, and led to a statistically significant reduction in hypoglycemic events, Dr. Jay S. Skyler said at the annual meeting of the European Association for the Study of Diabetes. In addition to these improvements in insulin management, the study results also showed that the hyaluronidase formulation was noninferior to insulin alone for reducing hemoglobin A1c levels, and also had a similar safety and tolerability profile in type 1 patients, said Dr. Skyler, professor and deputy director of the diabetes research institute of the University of Miami.
http://www.clinicalendocrinologynew...ursions/74d5016961f4c5f32d80b1056e5622a3.html